Market Overview:
The India idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 9.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) refers to an infectious lung disease that causes the buildup of scar tissues in the lungs, which reduces their oxygen-carrying functionalities. It is diagnosed through various chest imaging evaluations, including lung biopsies, antibody tests, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs containing nintedanib and pirfenidone salts, which slows the rate of scar tissue formation and controls the associated symptoms. Supportive therapeutic options, including palliative care and oxygen therapy, are also provided as effective treatment methods for IPF.
India Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the India IPF treatment market growth. The rising awareness regarding the availability of effective strategies for preventing and managing IPF is acting as another growth-inducing factor. In line with this, rapid economic growth and advancements in diagnostic and treatment methods are further propelling the market growth. Moreover, extensive research and development (R&D) activities for introducing novel medications and increasing improvements in the healthcare infrastructure are positively influencing the market growth across the country.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the India idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Hospitals
- Long-term Care Facilities
- Others
Breakup by Region:
- North India
- West and Central India
- South India
- East India
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Million |
| Segment Coverage |
Drug Class, End User, Region |
| Region Covered |
North India, West and Central India, South India, East India |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the India idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the India idiopathic pulmonary fibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the India idiopathic pulmonary fibrosis treatment market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 India Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North India
8.1.1 Market Trends
8.1.2 Market Breakup by State
8.1.3 Market Forecast
8.2 West and Central India
8.2.1 Market Trends
8.2.2 Market Breakup by State
8.2.3 Market Forecast
8.3 South India
8.3.1 Market Trends
8.3.2 Market Breakup by State
8.3.3 Market Forecast
8.4 East India
8.4.1 Market Trends
8.4.2 Market Breakup by State
8.4.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Policy and Regulatory Landscape
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
List of Figures
Figure 1: India: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 4: India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 5: India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 6: India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2021
Figure 7: India: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: India: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: India: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: India: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: India: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: India: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: India: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: India: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: India: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: India: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: India: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: India: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: North India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: North India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by State (in %), 2021
Figure 21: North India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: West and Central India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: West and Central India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by State (in %), 2021
Figure 24: West and Central India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: South India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: South India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by State (in %), 2021
Figure 27: South India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: East India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: East India: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by State (in %), 2021
Figure 30: East India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 33: India: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: India: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: India: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: India: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players